The government’s idea is to bring drugs and treatments for this disease to the commercial market, having covered these costs since the pandemic began.
The United States is the country with the highest number of deaths from the coronavirus SARS-CoV-2. (Photo: PL)
US President Joe Biden’s administration could stop paying for vaccines and treatments against Covid-19, which would mean high costs for around 30 million people without health insurance this Friday.
The government intends to bring the drugs and treatments for this disease to the commercial market, having borne those costs since the pandemic began, La Opinion newspaper reported this Friday.
White House Covid-19 response coordinator Ashish Jha said the executive branch is studying how to transition from the “acute emergency phase” of the pandemic, during which the state will stop purchasing most tests, vaccines and treatments.
On August 30, the Department of Health and Human Services (HHS) will hold a meeting with representatives from drug companies, pharmacies and state health officials interested in a Covid-19 treatment industry, The Wall reported. StreetJournal.
An HHS spokesman estimated it would take months for payments for Covid-19 drugs and vaccines to be transferred to the commercial market.
Once again, the big winners of this decision would be the pharmaceutical companies, in this case Pfizer, BioNtech and Moderna, which manufactured the main vaccines used in this country.
Pfizer alone reported second-quarter sales of $8.1 billion for its Covid-19 drug Paxlovid, which was used to treat President Biden.
Both the administration of former President Donald Trump (2017-2021) and the current one always planned to shift the cost of vaccines and treatments against the disease from the government to the individual, a path that is already being traced, the article commented in La opinion.
The United States is the country with the highest number of deaths from the SARS-CoV-2 coronavirus, more than a million people, according to data from the CDC and media such as the New York Times.
